US FDA Lays Out High And Low Options At MDUFA Talks
This article was originally published in Clinica
Minutes from the most recent Medical Device User Fee Act negotiation meeting, posted by the US FDA, suggest regulators and industry are getting closer to agreeing on components of a MDUFA IV proposal. Returning to the negotiating table on May 16, the agency presented two proposals to industry that are approximately $30m apart.
You may also be interested in...
FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.